HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief

This article was originally published in The Rose Sheet

Executive Summary

To consider new data, Europe’s Scientific Committee on Consumer Safety plans to take another look at the safety of parabens in cosmetic products. More news in brief.

You may also be interested in...



Soldiering Through Scrutiny, Nu Skin Launches Growth Plan For China

Nu Skin aims to achieve “higher levels of penetration” in China by expanding its direct-selling platform to additional provinces and tripling the number of stores and sales centers it operates by 2017. Meanwhile, short-seller Citron Research directs FDA and FTC to advertising for Nu Skin’s ageLOC line, which it asserts is rife with “unsubstantiated medical claims.”

CIR Panel Affirms Paraben Safety, Will Investigate Infant Skin Properties

With parabens’ use in infant products coming under scrutiny abroad, the CIR Expert Panel intends to learn more about how infant skin reacts to personal-care products. However, the panel maintains its 2006 “safe as used” assessment for parabens.

CIR To Consider Re-Review Of Parabens Following Europe’s New Guidance

Following Denmark’s decision to ban parabens in children’s cosmetics and the EC Scientific Committee on Consumer Safety’s recently revised opinion for parabens acknowledging a possible risk in diaper products for children under 6 months of age, the Cosmetic Ingredient Review Expert Panel may consider re-reviewing the ingredient group.

Related Content

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018348

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel